https://www.selleckchem.com/pr....oducts/phycocyanobil
n to be acceptable with high procedural success and excellent SB protection. Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing tamoxifen with the approval of the oncologist is the major treatment for cases with tamoxifen-induced retinopathy. We herein reported a patient with a two-year history of painless and reduced visual acuity in both